What Memphis does

Memphis Pharmaceuticals & Chemical Industries is an Egyptian pharmaceutical manufacturer established in 1940, headquartered at 8 El Sawah Street, El Amiriya, Cairo, and operating as a subsidiary of the state-owned Egyptian Holding Company for Pharmaceuticals. The company is publicly listed on the Egyptian Exchange under ticker MPCI and employs more than 1,200 staff across five domestic offices, with distribution extending through international agents to 10+ countries in the Middle East and Africa.

The company manufactures 145+ products across 15 GMP-compliant production lines, spanning a broad therapeutic portfolio in human health — antibiotics (Garamycin, Levoflox, Azithroheal, Cipro), NSAIDs and analgesics (Ibufen, Celecox, Cetamol), corticosteroids (Betason, Dexamethasone, Diprosone), gastrointestinal and cardiovascular agents, antihistamines, vitamins and mineral supplements, dermatologicals, and respiratory products — alongside a veterinary line covering anti-coccidiosis, anthelmintics, tetracyclines, and lincomycin-spectinomycin combinations. Manufacturing is supported by an internal R&D center and pipeline, with operations subject to periodic surveillance by international and local health authorities.

Memphis generates revenue through one-time sale of pharmaceutical products distributed directly to Egyptian healthcare providers, pharmacies, and patients via its captive network of scientific centers and sales offices, with international sales routed through agents in MEA export markets. The business is sales-led with no disclosed direct-to-consumer pricing. In FY 2024-2025 the company reported sales of EGP 1.5 billion (versus EGP 871.9 million prior year) and net profit of EGP 504.92 million, a 164% year-on-year increase, while nine-month figures ending March 2025 showed revenue growth of 65.1% YoY to EGP 1.097 billion and a 46.2% gross margin.

Name

Memphis

Legal name

Memphis Company for Pharmaceuticals and Chemical Industries

Website

https://memphis.com.eg

Company type

Private

Founded year

1940

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Memphis Pharmaceuticals & Chemical Industries is a Cairo-based, state-owned Egyptian pharmaceutical manufacturer founded in 1940, producing 145+ GMP-compliant human and veterinary medicines across 15 production lines for domestic pharmacies and clinics, with exports to 10+ Middle East and African countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

akta.pro secondary industry

Veterinary Vaccine & Biologics Distributors (HLAMAIAC)

Keywords

• Pharmaceutical manufacturing
• Human pharmaceuticals
• Veterinary medicines
• Generic drug production
• Antibiotic formulations

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of pharmaceutical products for human and animal health across multiple therapeutic categories including antibiotics, anti-inflammatory, cardiovascular, vitamins, and more. Revenue generated from domestic Egyptian market and exports to Middle East and Africa.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Memphis manufactures and distributes human and veterinary pharmaceutical products across multiple therapeutic categories, including antibiotics, anti-inflammatory, cardiovascular, dermatological, and vitamin formulations. It operates 15 production lines producing more than 145 products from its Cairo base, supplying pharmacies, hospitals, clinics, veterinarians, and government health agencies across Egypt and export markets.

Product overview

Memphis Pharmaceuticals and Chemical Industries is an Egyptian pharmaceutical company established in 1940, operating as a subsidiary of the Egyptian Holding Company for Pharmaceuticals. The company manufactures a comprehensive portfolio of human health products and animal health (veterinary) products. Human products include antibiotics (Garamycin, Levoflox, Clarimycin, Azithroheal, Cipro, Noracin), NSAIDs and analgesics (Ibufen, Celecox, Indacin, Cetamol), corticosteroids (Betason, Dexamethasone, F-Corten, Diprosone, Diprosalic), gastrointestinal medications (Famotin, Omepral, Spasmocin, Detrusan, Purgaton), cardiovascular medications (Irbetan, Edemex, Vasorin), antihistamines (Fexodine, Zylofen, Pirafene, Coldact), vitamins and supplements (Trivarol, Devarol-S, Cevarol, Folic Acid, Magnisol, Calcionat), dermatologicals (Ultra-Medanin, Miconol, Beclozone, Memphis Carbamide), and other therapeutic categories. Veterinary products include antibiotics, anti-coccidiosis, anthelmintics, and analgesics. The company operates 15 production lines across its facilities in Cairo, Egypt.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibiotic pharmaceuticals Antibiotic formulations produced by Memphis for human healthcare use, supplied to pharmacies, hospitals, clinics, and government health agencies across Egypt and export markets.
• Anti-inflammatory pharmaceuticals Anti-inflammatory drug formulations manufactured for the treatment of pain and inflammation, supplied to institutional healthcare buyers in Egypt and export markets.
• Cardiovascular pharmaceuticals Cardiovascular drug formulations manufactured for patients with heart and circulatory conditions, supplied to pharmacies, hospitals, and government health agencies.
• Vitamin and nutritional supplements Vitamin and nutritional supplement formulations manufactured by Memphis for human health maintenance, supplied to pharmacies and healthcare institutions.
• Dermatological pharmaceuticals Dermatological drug formulations manufactured for the treatment of skin conditions, supplied to pharmacies, hospitals, and dermatology clinics.
• Veterinary medicines Veterinary pharmaceutical formulations produced by Memphis for the treatment of animal diseases, supplied to veterinarians, livestock operations, and animal health distributors.

Quantifiable outcome

• 164% year-on-year profit increase in fiscal year 2024-2025
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Egyptian Holding Company for PharmaceuticalscoreStrategic or Co-development PartnerParent company and subsidiary relationship. Memphis Pharmaceuticals is a subsidiary of the Egyptian Holding Company for Pharmaceuticals, part of the Ministry of Public Business Sector's strategy to revive and develop assets of affiliated companies.

Scale indicators13 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Hikma Pharmaceuticals: MENA-origin, London-listed multinational generics and specialty pharmaceutical manufacturer with significantly larger scale and broader international footprint; a regional incumbent peer operating in the same therapeutic categories with much deeper market reach.
• Cipla: India-based global generic pharmaceutical manufacturer with deep presence across emerging markets including Africa; competes with Memphis in respiratory, antibiotics, and OTC categories, particularly in African export markets.
• Zoetis: Largest global animal health company; competes with Memphis in veterinary pharmaceuticals across MENA/Africa markets, though at significantly higher scale and broader product range.
• Aurobindo Pharma: Large Indian generic manufacturer with significant African and emerging-market distribution; competitive in the same generic therapeutic categories where Memphis operates (antibiotics, anti-infectives, vitamins).
• GSK: Global multinational pharmaceutical major with broad antibiotics, vaccines, and consumer health portfolios; competes with Memphis in several therapeutic categories across MENA/Africa, particularly in regulated tenders and branded generics.

Direct peers

• Vetoquinol: Global veterinary pharmaceutical company specializing in animal health products including antibiotics, parasiticides, and anti-coccidials; directly comparable to Memphis's veterinary segment (anthelmintics, anti-coccidiosis, tetracyclines) on product and customer overlap.
• EIPICO (Egyptian International Pharmaceutical Industries Company): Egyptian pharmaceutical manufacturer and fellow subsidiary of Egyptian Holding Company for Pharmaceuticals, making it a state-owned peer with directly comparable product portfolio, manufacturing footprint, and GTM in the Egyptian market.
• Eva Pharma: Egyptian-headquartered pharmaceutical manufacturer with broad generic and specialty pharma portfolio across human and animal health; the closest direct regional peer serving the same MENA/Africa markets with overlapping product categories.
• Amriya Pharmaceutical Industries: Egyptian pharmaceutical manufacturer producing generics across multiple therapeutic categories with regional distribution; comparable in scale, product mix, and Egyptian/MENA market positioning.
• Pharco Pharmaceuticals: One of the largest Egyptian pharmaceutical manufacturers with a broad generic portfolio spanning human therapeutics and significant MENA/Africa distribution; comparable in scale, product breadth, and export orientation to Memphis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Memphismemco
• Facebookfacebook.com/memphisPharmaceuticals
• LinkedInlinkedin.com/in/memphis-pharmaceuticals-259b7a3b2

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Memphis